

0040-4020(95)00853-5

Chiral Non-racemic Bis(vicinal 1,2-Diamines): 4,5-Diamino-*N*-(3,4-diaminobutyl)pentanamide Tetrahydrochloride, *N,N'*-Bis[3,4-bis(*t*-butoxycarbonylamino)butyl]urea and *N,N'*-Bis[3,4-bis(*t*-butoxycarbonylamino)butyl]hexanamide[†]

Janina Altman and Wolfgang Beck*

Institut für Anorganische Chemie der Universität München, Meiserstr. 1, D-80333 München, Germany


Abstract: The reaction of (*R*) or (*S*)-*N*⁴,*N*⁵-bis(*t*-butoxycarbonyl)-4,5-diaminopentanoic acid (**6**) with (*R*) or (*S*)-*N*³,*N*⁴-bis(*t*-butoxycarbonyl)-3,4-diaminobutylisocyanate (**8**) catalyzed by 4-dimethylamino pyridine (DMAP), leads to the synthesis of (*R,R*), (*S,S*), (*R,S*) and (*S,R*) isomeric amides (**11 a - d**). The addition of adipic acid monomethyl ester to (*R*) or (*S*) isocyanate, followed by saponification, acidification and subsequent reaction with the second molecule of (*R*) or (*S*) isocyanate allows isolation of the (*R,R*), (*S,S*) and the meso isomers of *N,N'*-bis[3,4-bis(*t*-butoxycarbonylamino)butyl]hexanediamide (**17**). Removal of protecting groups with HCl/EtOH affords chiral non-racemic molecules having two free vicinal diamine units.

Vicinal diamines and triamines are important ligands for *cis*-platinum complexes¹. Recently there has been a growing interest in platinum complexes capable of intra and interstrand-DNA binding and forming DNA-protein linkage². We have reported the synthesis of chiral racemic dicarboxylic acid bis(1,2,4-triaminobutane-*N*⁴) amides³ in which two 1,2,4-triaminobutane units are bridged as α,ω -dicarboxylic acid amides with two vicinal diamines yielding bis[platinum(II)] complexes. These complexes in which two *cis*-PtCl₂ fragments are bridged by a spacer show a pronounced interstrand binding ability⁴. Independently we developed a stereospecific synthesis of selectively protected (*S*)-1,2,4-triaminobutanes using (*S*)-pyroglutamic acid methyl ester as a source of chirality⁵. The enantiomeric purity was confirmed by ¹³C NMR spectra of their (-)-menthyl carbamate derivatives⁶.

Now we report the synthesis of the (*R*) isomer in order to obtain compounds containing two vicinal diamine units in all isomeric forms, to study the influence of configuration on DNA-interstrand binding. The selectively protected chiral 1,2,4 triamines may lead to three systems: one in which (*R*) or (*S*)-*N*¹,*N*²-di-Boc-1,2,4-triaminobutane (Boc = butoxycarbonyl) is bound to (*R*) or (*S*)-*N*⁴,*N*⁵-di-Boc-4,5-diaminopentanoic acid; the other in which two molecules of (*R*) or (*S*)-*N*¹,*N*²-di-Boc-1,2,4-triaminobutane are bridged as dicarboxylic acid bis(amides); a third one with urea type linked amines. Starting from (*R*)-pyroglutamic acid methyl ester, the (*R*)-*N*³,*N*⁴-di-Boc-3,4-diaminobutylisocyanate (**8a**) has been prepared by the same procedure as for the previously reported (*S*) isomer⁵ (Scheme 1). Thus, the ester was reduced by LiBH₄ to the known *R*-(hydroxymethyl)-2-pyrrolidone⁷; the alcohol was converted by the Mitsunobu reaction⁸ with hydrazoic acid to (*R*)-azide (**1**) which was catalytically reduced to (*R*)-5-(aminomethyl)-2-pyrrolidone (**2**). The single set of signals in the ¹³C NMR spectrum for the diastereotopic carbons of (1*R*, 3*R*, 4*S*)-menthyl carbamate (**4**) confirmed its optical purity. Amine **2** was converted to the di-Boc lactam derivative **5** in a two-step one-pot reaction (Rf = 0.30, EtOAc; NH absorption at 3440 cm⁻¹, CHCl₃). Nucleophilic ring opening of **5** by LiOH in THF/water and acidification led to (*R*)-*N*⁴,*N*⁵-di-Boc-4,5-diaminopentanoic acid **6**. Using a mixed anhydride

method **6** was transformed to acyl azide **7** (IR absorption at 2155 cm^{-1}), which underwent Curtius rearrangement to the isocyanate **8** (2260 cm^{-1}). In small scales (0.1 mmol) **8** was converted with LiOH to (*R*)-*N*¹,*N*²-di-Boc-1,2,4-triaminobutane (**9**) (see Scheme 1). In larger quantities the formation of the corresponding urea was also observed.


Previously we have shown that the preparation of the mixed urethane (*S*)-*N*¹,*N*²-di-Boc-*N*⁴-*Z*-1,2,4-triaminobutane⁵ does not require isolation of the amine **9** and the acyl function in position 4 is introduced by addition of benzyl alcohol to isocyanate **8b** in the presence of catalytical amount of *p*-toluenesulfonic acid (*p*-TSA). Under the above conditions amidation with acids did not occur but **8b** reacted with isobutyric acid using DMAP⁹ as catalyst to give the amide **13b** in 78% yield.



Scheme 1.

The reaction of the isocyanate **8a** with the acid **6a** afforded the amide **11a** with the configuration (*R,R*) (mp $178-9^\circ$, $[\alpha]_D^{24} +34.6$). The (*S,S*) enantiomer **11b** was obtained by reacting the isocyanate **8b** with the (*S*)-

acid **6b** (mp 178-9°, $[\alpha]^{24}_D$ -34.8). The second enantiomeric pair (*R,S*) **11c** (mp 194°, $[\alpha]^{24}_D$ +37.0) and (*S,R*) **11d** (mp 195°, $[\alpha]^{24}_D$ -37.8) was obtained by reacting the isocyanate **8a** with the acid **6b** and **8b** with **6a**, respectively (see Scheme 2).



a) (*R,R*), b) (*S,S*), c) (*R,S*), d) (*S,R*)


Scheme 2.

The (*R,S*) and (*S,R*) isomers of **11** were purified by trituration and crystallisation whereas the less polar (*R,R*) and (*S,S*) isomers required silica gel column purification to remove unchanged acid. (Yields of 60-70% were obtained by chromatographic means of isolation whereas triturations and crystallization afforded 50% yields). Formation of urea as a side product was not observed. The diastereomers differ in their melting points and in their solubilities. No differences between them was observed in NMR spectra. In the ¹³C NMR spectra the C-1 and the C-9 atoms have the same chemical shifts, the C-8 atom absorbs at a lower field than C-2. (The numbering of carbons in the NMR spectra, for sake of comparison with the previously reported data, refers to 1,2,4-triaminobutane). The assignment is based on comparison with **10** and **13** as model compounds. All proton NMR signals are very broad due to hindered rotation imposed by Boc protecting groups¹⁰. The isomers were characterized by their retention time on a ChiraDex^R column. The retention times of the (*R,R*), (*S,S*), (*R,S*) and

(*S,R*) isomers **11** were 19.82, 23.45, 18.18 and 20.19 min respectively. The behaviour of each enantiomeric pair was investigated separately which allowed the verification of their enantiomeric purity. The removal of Boc-protecting groups with dry HCl in EtOH afforded hygroscopic tetraamines as hydrochlorides **12a-d**.

The approach to the (*R,R*) and (*S,S*) isomers of *N,N'*-[3,4-bis(*t*-butoxycarbonylamino)butyl]hexanamide (**17**), by reacting *S* or *R* isocyanate **8** with adipic acid in the presence of DMAP in benzene, led to the formation of urea **14** instead of the expected bisamides. The formation of **14** was also observed in the absence of DMAP. The low solubility of adipic acid in benzene or in chloroform and its acidity are probably responsible for this reaction. The synthesis of the compounds **17** was achieved by a stepwise procedure. The isocyanate **8** reacted with the monomethyl ester of adipic acid which is highly soluble in benzene. The resulting ester **15** was saponified to the acid **16** which subsequently reacted with the second molecule of isocyanate **8**. By this method all three (*R,R*), (*S,S*) and meso (*R,S*) isomers of bisamide **17** were prepared (see Scheme 3).

It should be noted that the by-product **14** contains two potential vicinal diamine units linked as urea. There has recently been a growing interest in urea linked amino acids, amines and diamines¹¹ due to the higher metabolic stability of the urea linkage compared to the amide linkage.




Scheme 3.

The retention times of the (*R,S*), (*R,R*) and (*S,S*) isomers **17** on a ChiraDexR column were 20.07, 21.79 and 23.53 min respectively whereas that of urea **14** was 16.92 min for the (*R,R*) isomer and 20.18 min for the (*S,S*) isomer.

Addition of the monomethyl ester of adipic acid to **8** rarely exceeded 50% yield and was accompanied by formation of the urea **14**. The addition of **8** to **16**, under the same conditions, was in the range of 60-70%. (Yields are reported on isolated compounds after trituration and chromatography. Trituration removed the unchanged acid **16** with a *R_f* very close to that of the bisamide **17**, whereas a silica gel column was efficient in separation of the urea **14** from **17**).

The addition of different acids to the isocyanate **8** to form the amides **11**, **13**, **15**, **17** and urea **14**, using DMAP as catalyst, calls for some comments. According to the mechanism proposed by Steglich⁹, DMAP and isocyanate form a dipolar complex **19** which undergoes protonation to the reactive *N*-carbamoylpyridinium ion **20**. Apparently the nature of the acid present in the mixture also has an influence on the reaction pathway. Carboxylates of branched acids react with **20** to form probably a mixed carbamic acid anhydride **21** which loses CO₂ to give the expected amides (pathway *a*). Non-branched acids react with the *N*-carbamoylpyridinium ion but, in addition, they also react with the mixed anhydride, releasing free carbamic acid **24** which subsequently gives rise to amine **25** (pathway *b*). The amine then reacts with **20**, or with isocyanate, to give urea. In the presence of isobutyric acid and substituted 4,5-diaminopentanoic acid the pathway *a* is the predominant one.



Scheme 4.

The reactions of phenylacetic acid with phenylisocyanate or with 6-isocyanatopenicillanic acid also follow pathway *a*¹². In the case of adipic acid monomethyl ester both pathways, *a* and *b*, give a mixture of amide and urea. More acidic acids, like dicarboxylic acids, do not require the intermediacy of DMAP. Direct addition to isocyanate, release of carbamic acid and its decarboxylation to amine will lead to urea as a single reaction product.

In summary, by addition of acids to isocyanate **8** chiral non-racemic molecules containing two vicinal diamino units bound as amides, bisamides or urea were prepared in all isomeric forms. The removal of the Boc protecting groups and the reaction with K₂PtCl₄ will lead to optically active bis[platinum(II)] complexes.

EXPERIMENTAL

Melting points are uncorrected. Flash chromatography was carried out on silica gel (Merck, 70-230 mesh), TLC was performed on Merck Kieselgel 60 F₂₅₄ plates and ethanolic 0.2% ninhydrin was used for visualization. Data for the compounds **1a** - **9a**: Infrared spectra were recorded on a Perkin Elmer 298 spectrophotometer. ¹H and ¹³C NMR were measured on an AM Bruker 400 MHz WB spectrometer. Mass spectra were obtained on a TSQ-70 mass spectrometer and on a Varian Mat 711 double focusing mass spectrometer. Specific rotation was measured with a DIP JASCO polarimeter. Elemental analyses were performed by the Microanalytical Services of the Chemistry Department at the Hebrew University, Jerusalem. Data for the compounds **10** - **17**: IR spectra were measured on a Nicolet 520 FT-IR spectrometer. ¹H and ¹³C NMR spectra were recorded on a Jeol EX-400 instrument. Specific rotation was measured with a 241 Perkin Elmer polarimeter. HPLC: chromatography pump 655-A12 (Merck - Hitachi), UV detector, 210 nm (Bischoff), integrator D-2000 (Merck-Hitachi), LiChroCart^R 250-4 ChiraDex^R, HPLC-cartridge (250 x 4 mm) and LiChroCart^R RP18 precolumn (4 x 4). C, H, N analyses were performed with a Heraeus VT. (*R*) and (*S*)-Pyroglutamic acids were obtained from Merck-Schuchard.

The compounds **1a** - **9a** were prepared according to the procedure reported for the S series⁵.

(*R*)-5-(Azidomethyl)-2-pyrrolidone (1a):

Mp 62-63°; [α]_D³⁰ - 72.0 (c 5, EtOH); IR (CHCl₃): 2104 cm⁻¹; ¹H NMR (CDCl₃): δ 1.76 (m, 1H, AB part of ABCD CH₂); 2.21 (m, 1 H, AB part of ABCD, CH₂); 2.24 - 2.41 (m, 2 H, CH₂CO); 3.12 (dd, 1 H, AB part of ABX, CH₂N₃); 3.36 (dd, 1 H, AB part of ABX, CH₂N₃); 3.77 (q, 1 H, CHN); 7.29 (br, 1 H, NH); ¹³C NMR (CDCl₃): δ 23.9 (C-4); 29.7 (C-3); 53.6 (C-6); 55.9 (C-5); 178.5 (C-2). CIMS: *m/z* 141 [MH]⁺ (100%). C₅H₈N₄O requires 140.

(*R*)-5-(Aminomethyl)-2-pyrrolidone (2a):

Oil. [α]_D³⁰ - 37.0 (c 2, EtOH); ¹H NMR (CDCl₃): δ 1.80 (m, 1 H, part of ABCD, CH₂); 2.04 (s, 2H, NH₂); 2.09 (m, part of ABCD, 1 H, CH₂); 2.20 (m, 2 H, CH₂CO); 2.54 (dd, 1 H, AB part of ABX, CH₂N); 2.78 (dd, 1 H, AB part of ABX, CH₂N); 3.56 (q, 1 H, CHN); 7.74 (br, 1 H, NH); ¹³C NMR (CDCl₃): δ 23.9 (C-4); 30.1 (C-3); 47.1 (C-6); 56.7 (C-5); 178.5 (C-2); HRMS: *m/z* 114.0756 [MH]⁺ (1.2%); 97.0551 [M - NH₃]⁺ (35.8%); 85.0492 [M - CH₂NH₂]⁺ (78%); 84.0422 [M - CH₂NH₃]⁺ (100%); C₅H₁₀N₂O requires 114.0793.

(*R*)-5-(*t*-Butoxycarbonylaminoethyl)-2-pyrrolidone (3a):

Oil; [α]_D²⁸ - 12.1 (c 2, EtOH); IR (CHCl₃): 3439, 1700 cm⁻¹; ¹H NMR (CDCl₃): δ 1.39 (s, 9 H, Me); 1.74 (m, 1H, AB part of ABCD, 1H, CH₂); 2.15 (m, part of ABCD, 1H, CH₂); 2.30 (m, 2 H, CH₂CO); 3.05 (m, 1 H, AB part of CH₂N); 3.28 (m, 1H, AB part of CH₂N); 3.74 (m, 1H, CHN); 5.34 (br, 1H, NH); 7.04 (br, 1 H, NH); ¹³C NMR (CDCl₃): δ 24.1 (C-4); 28.3 (Me); 30.0 (C-3); 45.4 (C-6); 54.8 (C-5); 79.7 (CMe₃); 156.2 (CO₂); 178.5 (CO); CIMS: *m/z* 215 [MH]⁺ (100%). C₁₀H₁₉N₂O₃ requires 215. Anal. Found: C, 54.03; H, 8.10. C₁₀H₁₈N₂O₃ · 1/2H₂O requires C, 53.81; H, 8.52%.

(*R*)-5-[(1*R*, 3*R*, 4*S*)-Menthylloxycarbonylaminoethyl]-2-pyrrolidone (4a):

Mp 127-129°; [α]_D³⁰ - 58.9 (c 2, EtOH); IR (CHCl₃): 3440, 1695 cm⁻¹; ¹H NMR (CDCl₃): δ 0.74 (d, 3H, Me); 0.98 (d, 3H, Me); 1.00 (d, 3H, Me); 0.9 - 1.97 (m, 9H, cyclohexyl); 1.7-1.8 2.05-2.22 (m, 1H, part of AB, CH₂-4); 3.32(t, 2H, CH₂CO); 3.10-3.15 (q, 1H, part of AB, CH₂CO); 3.31-3.35 (m, 1H, part of AB, CH₂N); 3.76 (s br, 1H, CHN); 4.49 (q, 1H, CHO); 5.44 (s, 1H, NH); 7.06 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 16.5 (Me); 20.7 (Me); 22.0 (Me); 23.6 (C-5); 24.2 (C-8); 26.3 (C-4); 30.0 (C-1); 31.3

(C-3); 34.3 (C-6'); 41.4 (C-2'); 45.7 (C-6'); 47.4 (C-6); 54.7 (C-5); 74.8 (C-3'); 156.8 (CO₂); 178.5 (CO); CIMS: m/z 297 [MH]⁺ (100%). C₁₆H₂₉N₂O₅ requires 297. Anal. Found: C, 64.86; H, 9.50; N, 9.41. C₁₆H₂₈N₂O₅ requires C, 65.05; H, 9.21; N, 9.48%

(R)-5-(*t*-Butoxycarbonylaminoethyl)-1-(*t*-butoxycarbonyl)-2-pyrrolidone (5a):

5a was prepared from **2a**. Mp 133°C; [α]_D³⁰ + 60.5 (c 2, EtOH); IR (CHCl₃): 3440, 1780, 1730sh, 1710 cm⁻¹; ¹H NMR (CDCl₃): δ 1.33 (s, 9H, Me); 1.43 (s, 9H, Me); 1.85-2.03 (m, 2H, CH₂-4); 2.28-2.56 (m, 2H, CH₂CO); 3.26-3.34 (m, 2H, CH₂N); 4.11(m, 1H, CHN); 4.98 (t, 1H, NH); ¹³C NMR (CDCl₃): δ 21.1 (C-4); 27.9, 28.2 (Me); 31.4 (C-3); 42.9 (C-6); 57.8 (C-5); 79.5, 83.1 (C(Me)₃); 150.0, 156.0 ((CO₂)); 174.2 (CO); CIMS: m/z 315 [MH]⁺ (15%). C₁₅H₂₆N₂O₃ requires 315. Anal. Found: C, 57.60; H, 8.36; N, 8.87. C₁₅H₂₆N₂O₃ requires C, 57.32; H, 8.33; N, 8.91%

(R)-N⁴,N⁵-Bis(*t*-butoxycarbonyl)-4,5-diaminopentanoic acid (6a):

Mp 129-131°C; [α]_D²⁴ +12.2 (c 2, EtOH); IR (nujol): 3440, 1700 cm⁻¹; ¹H NMR (CDCl₃): δ 1.44 (s, 18H, Me); 1.62-1.82 (m, 2H, CH₂CO); 2.30-2.40 (m, 2H, CH₂CO); 3.1-3.2 (m, 2H, CH₂N); 3.64 (m, 1H, CHN); 4.91(d, 1H, NH); 5.00 (t, 1H, NH); ¹³C NMR (CDCl₃): δ 27.7 (C-3); 28.3 (Me); 44.6 (C-5); 51.0 (C-4); 79.5 (C(Me)₃); 156.4, 156.7 (CO₂); 177.2 (CO₂H); Anal. Found: C, 54.31; H, 8.56; N, 8.85. C₁₅H₂₈N₂O₆ requires C, 54.21; H, 8.49; N, 8.42%.

(R)-N³,N⁴-Bis(*t*-butoxycarbonyl)-3,4-diaminobutylisocyanate (8a):

Isobutyl chloroformate (544 mg, 4 mmol) was added to a mixture of **6a** (662 mg, 2mmol) and Et₃N (505 mg, 5mmol) in dry THF (16mL) at 0°C. After 1 h, NaN₃ (2.4 g.) in 8 mL of water was added and the reaction mixture stirred for 30 min at 0°C. EtOAc (80 mL) was added. The organic layer was separated, washed once with water, dried (Na₂SO₄), concentrated and dried in vacuo at room temperature for 5 h. The IR (nujol) of the crude acyl azide **7** had an absorption at 2155 cm⁻¹. The residue was redissolved in benzene (70 mL) and heated at 60°C for 1 h. Benzene was evaporated yielding quantitatively the isocyanate **8a**, (630 mg) mp 99-102°C. [α]_D²⁴ +68.0 (c 2.07, benzene); IR (nujol): 3377, 3355, 2271, 1697, 1682, 1528 cm⁻¹; ¹H NMR (CDCl₃): δ 1.41 (s, 18H, Me); 1.50-1.82 (m, 2H, CH₂-2); 3.16 (m, 2H, CH₂N-4); 3.40 (t, 2H, J=6.8, CH₂N-1); 3.72 (m, 1H, CHN-2); 4.80 (br, 1H, NH); 4.90 (br, 1H, NH); ¹³C NMR (CDCl₃): δ 28.3 (Me); 34.4 (C-2); 40.0 (C-4); 44.3 (C-1); 49.4 (C-3); 79.7 (C(Me)₃); 79.5 (C(Me)₃); 156.0, 156.1 (CO₂); 156.6 (N=C=O); Anal. Found: C, 54.94; H, 8.23; N, 12.91. C₁₅H₂₇N₃O₅ requires C, 54.69; H, 8.26; N, 12.45%.

(S)-N³,N⁴-Bis(*t*-butoxycarbonyl)-3,4-diaminobutylisocyanate (8b):

The full IR and NMR data of **8b** are the same as of **8a**. mp 98-101°C, [α]_D²⁴ -67.9 (c 1.55, benzene); Anal. Found: C, 54.75; H, 8.35; N, 12.76. C₁₅H₂₇N₃O₅ requires C, 54.69; H, 8.26; N, 12.45%.

(R)-N¹,N²-Bis(*t*-butoxycarbonyl)-1,2,4-triaminobutane (9a):

Mp 76-78°C; [α]_D²⁴ +26.8 (c 2, EtOH); IR (CHCl₃): 1700, 1498 cm⁻¹; ¹H NMR (CDCl₃): δ 1.38 (s, 18H, Me); 1.53 (br, 2H, CH₂); 1.93 (br, 2H, NH₂); 2.74 (t, 2H, CH₂NH₂); 3.14 (br, 2H, CH₂N-1); 3.69 (br, 1H, CHN); 5.05 (br, 1H, NH); 5.11 (br, 1H, NH); ¹³C NMR (CDCl₃): δ 28.3, 28.5 (Me); 36.2 (C-3); 38.4 (C-4); 44.7 (C-1); 49.3 (C-2); 79.2 (C(Me)₃); 156.0, 156.4 (CO₂); CIMS: m/z 304 [MH]⁺ (100%). C₁₄H₃₀N₃O₄ requires 304.

(S)-4,5-Bis(*t*-butoxycarbonylamino)-N-(*i*-butyl)pentanamide (10b):

Dicyclohexylcarbodiimide (227 mg, 1.1 mmol) was added to the cold solution of the acid **6b** (331 mg, 1 mmol) and *N*-hydroxysuccinimide (127 mg, 1.1 mmol) in CH₂Cl₂ (10 mL). The mixture was left overnight at 4°C and filtered from DCU.

Isobutylamine (352 mg, 2.8 mmol) was added to the active ester and the reaction mixture stirred 1 h at 0°C and overnight at ambient temperature. CH₂Cl₂ was evaporated, the residue mixed with EtOAc (50 mL) and water. The organic layer was washed twice with water, dried, concentrated and chromatographed on silica gel column. Traces of DCU were eluted with a mixture of 30% EtOAc/hexane and the product was eluted with 70% EtOAc/hexane (356 mg, 92%), mp 138°C (from EtOAc/hexane), $[\alpha]_D^{24}$ -57.5 (c 2, EtOH); IR (nujol): 3364, 1684, 1648, 1533 cm⁻¹; ¹H NMR (DMSO-d₆): δ 0.80 (d, 6H, Me), 1.36 (s, 18H, Me superimposed on m, 1H, part of AB CH₂-3); 1.61 (m, 2H, CH(Me)₂ and part of AB CH₂-3); 2.02 (m, 2H, CH₂CO); 2.82 (t, 2H, CH₂NH₂); 2.88 (br, 2H, CH₂N); 3.38 (br, 1H, CHN); 6.48 (d, 1H, NH); 6.69 (t, 1H, NH); 7.70 (t, 1H, NH); ¹³C NMR (DMSO-d₆): δ 20.1 (Me); 28.0, 28.2 (Me); 32.1 (C-3); 37.1 (CH); 43.8 (CH₂N); 45.9 (CH₂N); 50.1 (CHN); 77.4, 77.7 (C(Me)₃); 155.3, 155.7 (CO₂); 171.7 (CO). Anal. Found: C, 58.71; H, 9.62; N, 10.83. C₁₉H₃₇N₃O₅ requires C, 58.88; H, 9.62; N, 10.84%.

4,5-Bis(*t*-butoxycarbonylamino)-*N*-[3,4-bis(*t*-butoxycarbonylamino)butyl]pentanamide (11 a-d):

General Method: **6** (662 mg, 2 mmol), DMAP (80 mg) and isocyanate **8** (658 mg, 2 mmol) were stirred in benzene (80 mL) for 12 h. In the case of the reaction of **6a** with **8a** or **6b** with **8b**, EtOAc (100 mL) was added to dissolve the product. The solution was washed once with 5% citric acid to remove DMAP, once with water and once with 5% aq. NaHCO₃, dried (Na₂SO₄) and concentrated to a volume of 50 mL to which 10 g of silica gel was added. The solvent was evaporated and the adsorbed silica was introduced on the top of a silica gel column (40 g) prepared with a mixture EtOAc/hexane 1:2. Some impurities were eluted with the same mixture. **11a** or **11b** were eluted with EtOAc/hexane 3:1, (R_f = 0.43, EtOAc-5% MeOH, visualisation with ninhydrin). Traces of unreacted acid **6** were eluted with EtOAc (R_f = 0.24, EtOAc-5% MeOH). In the case of the reaction of **6a** with **8b** or **6b** with **8a** CHCl₃ (120 mL) was added to benzene the solution. After washing as above the more polar **11c** or **11d** were isolated by trituration with EtOAc (3 x 8 mL) and once with EtOH (10 mL).

11a: (936 mg, 76%) mp 178-179°C; $[\alpha]_D^{24}$ +26.0 (c 2, EtOH); IR (nujol): 3355, 1685, 1645, 1531 cm⁻¹; ¹H NMR (DMSO-d₆): δ 1.37 (s, 18H, Me); 1.4-1.7 (br, 2H, CH₂-3); 2.0 (m, 2H, CH₂CO); 2.90 (m, 5H, part of AB of CH₂-4, CH₂-1, CH₂-9,); 3.04 (m, 1H, part of AB of CH₂); 3.3-3.5 (m, 2H, CHN-2, CHN-8); 6.49 (d, 1H, NH); 6.55 (d, 1H, NH); 6.69 (t, 2H, NH-1 and NH-9); 7.64 (s, br, 1H, NH); ¹³C NMR ((DMSO-d₆) δ 27.8 (C-7); 28.1 (Me); 31.7 (C-3); 32.0 (C-6); 35.8 (C-4); 43.7 C-1 + C-9); 48.3 (C-2); 50.0 (C-8); 77.4, 77.5 (C(Me)₃); 155.3, 155.5 (CO₂) 171.6 (CO); HPLC (MeOH/H₂O 55:45, flow rate 1.00 mL/min, 200 bar) 18.92 min. Anal. Found: C, 56.32; H, 9.04; N, 11.21. C₂₉H₅₅N₅O₉ requires C, 56.38; H, 8.97; N, 11.33 %.

11b: (730 mg, 62%) mp 178-179°C; $[\alpha]_D^{24}$ -25.5 (c 2, EtOH); IR (nujol): 3355, 1685, 1645, 1531 cm⁻¹; ¹H NMR (DMSO-d₆): δ 1.37 (s, 18H, Me); 1.4-1.7 (br, 2H, CH₂-3); 2.0 (m, 2H, CH₂CO); 2.90 (m, 5H, part of AB of CH₂-4, CH₂-1, CH₂-9,); 3.04 (m, 1H, part of AB of CH₂-4); 3.3-3.5 (m, 2H, CHN-2, CHN-8); 6.49 (d, 1H, NH); 6.55 (d, 1H, NH); 6.69 (t, 2H, NH-1 and 9); 7.64 (s, br, 1H, NH); ¹³C NMR (DMSO-d₆): δ 27.8 (C-7); 28.1 (Me); 31.7 (C-3); 32.0 (C-6); 35.8 (C-4); 43.7 C-1 + C-9); 48.3 (C-2); 50.0 (C-8); 77.4, 77.5 (C(Me)₃); 155.3, 155.6 (CO₂) 171.6 (CO); HPLC (MeOH/H₂O 55:45, flow rate 1.00 mL/min, 200 bar) 23.21 min. Anal. Found: C, 56.34; H, 8.94; N, 11.27. C₂₉H₅₅N₅O₉ requires C, 56.38; H, 8.97; N, 11.33 %.

11c: (707mg, 57%) mp 195°C; $[\alpha]_D^{24}$ +14.8 (c 1, EtOH); IR (nujol): 3339, 1682, 1644, 1528 cm⁻¹; ¹H NMR (DMSO-d₆): δ 1.37 (s, 18H, Me); 1.4-1.7 (m, br, 2H, CH₂-3); 2.0 (m, 2H, CH₂CO); 2.90 (m, 5H, part of AB of CH₂-4, CH₂-1, CH₂-9,); 3.04 (m, 1H, part of AB of CH₂); 3.3-3.5 (m, 2H, CHN-2, CHN-8); 6.49 (d, 1H, NH); 6.55 (d, 1H, NH); 6.69 (s, br, 2H, NH); 7.64 (s, br, 1H, NH); ¹³C NMR (DMSO-d₆): δ 27.8 (C-7); 28.2 (Me); 31.8 (C-3); 32.0 (C-6); 35.8 (C-4); 43.8 (C-1 + C-9); 48.4 (C-2); 50.0 (C-8); 77.4, 77.5 (C(Me)₃); 155.3, 155.5 (CO₂) 171.6 (CO); HPLC (MeOH/H₂O 55:45, flow rate 1.00 mL/min, 200 bar) 18.18 min. Anal. Found: C, 56.32; H, 9.04; N, 11.21. C₂₉H₅₅N₅O₉ requires C, 56.38; H, 8.97; N, 11.33 %.

11d: (802 mg 65%) mp 195°C; $[\alpha]_D^{24}$ -13.8 (c 1, EtOH); IR (nujol): 3339, 1682, 1644, 1528 cm⁻¹; ¹H NMR (DMSO-d₆): δ 1.37 (s, 18H, Me); 1.4-1.7 (br, 2H, CH₂-3); 2.0 (m, 2H, CH₂CO); 2.90 (m, 5H, part of AB of CH₂-4, CH₂-1, CH₂-9); 3.04 (m, 1H, part of AB of CH₂); 3.3-3.5 (m, 2H, CHN-2, CHN-8); 6.49 (d, 1H, NH); 6.55 (d, 1H, NH); 6.69 (t, 2H, NH); 7.64 (t, 1H, NH); ¹³C

NMR (DMSO- d_6): δ 27.8 (C-7); 28.0 (Me); 31.7 (C-3); 32.0 (C-6); 35.8 (C-4); 43.7 C-1 + C-9); 48.3 (C-2); 50.0 (C-8); 77.4, 77.5 (C(Me)₃); 155.3, 155.6 (CO₂) 171.5 (CO); HPLC (MeOH/H₂O 55:45, flow rate 1.00 mL/min, 200 bar) 20.19 min; Anal. Found: C, 56.26; H, 9.17; N, 11.32. C₂₉H₅₅N₅O₉ requires C, 56.38; H, 8.97; N, 11.33 %.

4,5-Diamino-*N*-(3,4-diaminobutyl) pentanamide tetrahydrochloride (12 a-d):

General Method: **11** (617 mg, 1 mmol) was suspended in a solution of dry 2.5 M HCl in EtOH (10 mL) and the mixture was stirred at ambient temperature for 15 h and then heated at 50°C in water bath for 1 h, cooled and centrifugated. One trituration with EtOH (10 mL), three triturations with dry ether and drying in high vacuo at 50°C for 10 h yielded the hygroscopic tetrahydrochloride **12** in quantitative yields, containing with 0.5 - 1.0 mmol of EtOH.

12a: $[\alpha]_D^{24}$ -0.8 (c 2, EtOH); ¹H NMR (D₂O): δ 1.7-2.0 (m, 4H, CH₂-3 and CH₂-7), 2.37 (t, 2H, CH₂CO); 3.1-3.3 (m, 6H, CH₂-4, CH₂-1, CH₂-9,); 3.50-3.55 (m, 2H, CHN-2, CHN-8); ¹³C NMR (D₂O): δ 26.6 (C-6); 31.0 (C-7); 31.7 (C-3); 35.9 (C4); 41.5 (C-1); 41.7 (C-9); 48.1 (C-2); 50.0 (C-8); 175.7 (CO); Anal. Found: C, 32.48; H, 8.13; N, 16.31. C₉H₂₇Cl₄N₅O·CH₃CH₂OH requires C, 32.28; H, 8.12; N, 17.11 %

12b: $[\alpha]_D^{24}$ +0.9 (c 2, EtOH); ¹H NMR (CD₃OD): δ 1.7-2.1 (m, 4H, CH₂-3 and 7); 2.58 (t, 2H, CH₂CO); 3.20-3.35 (m, 6H, CH₂-1, CH₂-4, CH₂-9,); 3.48 (m, 1H, CHN); 3.72 (m, 1H, CHN); ¹³C NMR (CD₃OD): δ 27.4 (C-6); 31.3 (C-7); 32.3 (C-3); 35.9 (C4); 42.1 (C-9); 42.4 (C-1); 48.4 (C-2); 50.6 (C-8); 175.3 (CO); Anal. Found: C, 32.91; H, 8.22; N, 16.92. C₉H₂₇Cl₄N₅O·CH₃CH₂OH requires C, 32.28; H, 8.12; N, 17.11%

12c: $[\alpha]_D^{24}$ -2.9 (c 2, EtOH); IR (nujol): 3500-2900, 1643, 1608, 1558, 1498 cm⁻¹; ¹H NMR (D₂O): 1.7-2.1 (m, 4H, CH₂-3 and 7); 2.38 (t, 2H, CH₂CO); 3.2-3.3 (m, 6H, CH₂-1, CH₂-4, CH₂-9,); 3.50-3.55 (m, CHN-2, CHN-8,); ¹³C NMR (D₂O): δ 26.7 (C-6); 31.0 (C-7); 31.7 (C-3); 35.9 (C4); 41.5 (C-9); 41.7 (C-1); 48.1 (C-2); 50.0 (C-8); 175.7 (CO); Anal. Found: C, 31.44; H, 7.99; N, 15.91. C₉H₂₇Cl₄N₅O·1/2CH₃CH₂OH·H₂O requires C, 30.89; H, 8.26; N, 16.31 %

12d: $[\alpha]_D^{24}$ +2.4 (c 2, EtOH); IR (nujol): 3500-2900, 1643, 1608, 1558, 1498 cm⁻¹; ¹H NMR (D₂O): δ 1.7-2.1 (m, 4H, CH₂-3 and 7); 2.38 (t, 2H, CH₂CO); 3.2-3.3 (m, 6H, CH₂-1, CH₂-4, CH₂-9,); 3.50-3.55 (m, CHN-2, CHN-8,); ¹³C NMR (D₂O): δ 26.7 (C-6); 31.0 (C-7); 31.7 (C-3); 35.9 (C4); 41.5 (C-9); 41.7 (C-1); 48.1 (C-2); 50.0 (C-8); 175.7 (CO); Anal. Found: C, 31.39; H, 7.54; C₉H₂₇C₄N₅O·1/2CH₃CH₂OH requires C, 31.00; H, 7.87 %

(*S*)-*N*¹,*N*²-Bis(*t*-butoxycarbonyl)-*N*⁴-(isobutyryl)-1,2,4-triaminobutane (13b):

8b (329 mg, 1mmol), DMAP (50 mg) and isobutyric acid (1 mL) were stirred in benzene (40 mL) for 12 h. EtOAc (40 mL) was added and the mixture was washed with water, 5% citric acid, water, 10% aq NaHCO₃ dried (Na₂SO₄), and concentrated. The residue was absorbed on silica gel (5 g) and put on a silica gel column (10 g). Elution with 40% EtOAc/hexane afforded **13** (291 mg 78%), mp 154°C; $[\alpha]_D^{24}$ -35.1 (c 2, EtOH); IR (nujol): 3318, 1682, 1646, 1532cm⁻¹; ¹H NMR (DMSO- d_6) δ 0.97 (d, 6H, CH(Me)₂); 1.37 (s, 18H, CH(Me)₃); 1.34; 1.48 (m, 2H, CH₂-3); 2.28 (q, 1H, CH(Me)₂); 2.95 (m, 3H, CH-2 and part of AB CH₂-4); 3.04 (m, 1H, CH₂-4); 3.46 (m, 1H, CH-2 and part of AB CH₂-4,); 6.57 (d, 1H, NH-2); 6.73 (t, 1H, NH-1); 7.56 (t, 1H, NH-4); ¹³C NMR (DMSO- d_6) δ 19.5, 19.6 (CH(Me)₂); 28.2 (CH(Me)₃); 32.8 (C-3); 33.9 (CH(Me)₂); 35.4 (C-4); 43.8 (C-1); 48.3 (C-2); 79.5 (C-O); 155.3, 155.7 (CO₂); 175.7 (CO); Anal. Found: C, 58.36; H, 9.36; N, 11.04. C₁₈H₃₇N₃O₅ requires C, 57.88; H, 9.44; N, 11.25 %.

(*R*)-Methyl 5-[3,4-bis(*t*-butoxycarbonylamino)butylaminocarbonyl]pentanoate (15a):

Isocyanate **8a** (536 mg, 1.63 mmol), DMAP (60 mg, 0.5 mmol) and adipic acid monomethyl ester (288 mg, 1.8 mmol) were stirred in benzene (70 mL) for 12 h at ambient temperature. CHCl₃ (100 mL) was added to dissolve formed solids. The mixture was washed with 5% citric acid (to remove DMAP), water, 5% aq NaHCO₃, dried (Na₂SO₄) and concentrated. The residue was

trituration with EtOAc (20 mL). The sparingly soluble urea **14a** (205 mg, 40%) was removed by filtration. The solution was concentrated and chromatographed on silica gel column (25 g) prepared in 30% EtOAc/hexane. **15a** was eluted with 55% EtOAc-hexane: 342 mg, 47%, mp 66-67°C; $[\alpha]_D^{24} +26.2$ (c 1.86, EtOH); IR (nujol): 3340, 3297, 1739, 1678, 1631, 1528 cm^{-1} ; $^1\text{H NMR}$ (CDCl_3): δ 1.25-1.50 (s, 18H, Me and m, 2H, CH_2 -3); 1.66 (m, 4H, CH_2 -7 and 8); 2.25 (t, 2H, CH_2CONH); 2.36 (t, 2H, $\text{CH}_2\text{CO}_2\text{H}$); 2.88 (br, 1H, part of AB, CH_2 -4); 3.1 (br, 1H, part of AB, CH_2 -1); 3.24 (br, 1H, part of AB, CH_2 -1); 3.33 (m, 5H, CH-2, part of AB CH_2 -4 and OMe); 5.05 (br, 1H, NH); 5.19 (1H, NH); 7.01 (br, 1H, NH); $^{13}\text{C NMR}$ (CDCl_3): δ 24.4 (C-7); 25.1 (C-8); 28.3 (Me); 32.8 (C-3); 33.7 (C-9); 35.8 (C-4); 36.1 (C-6); 44.3 (C-1); 49.9 (C-2); 51.6 (OMe); 79.7, 79.8 ($\underline{\text{C}}(\text{Me})_3$); 157.1 (CO_2); 173.1 (CO); 174.1 (CO); Anal. Found: C, 56.71; H, 8.84; N, 9.29. $\text{C}_{21}\text{H}_{39}\text{N}_3\text{O}_7$ requires C, 56.61; H, 8.82; N, 9.43%.

(S)-Methyl 5-[3,4-bis(*t*-butoxycarbonylamino)butylaminocarbonyl]pentanoate (15b):

15b was prepared as described for **15a** from 709 mg of **8b**: (554 mg, 58%), mp 66-67°C; $[\alpha]_D^{24} -26.4$ (c 1.52, EtOH); IR (nujol): $^1\text{H NMR}$ (CDCl_3): δ 3340, 3297, 1739, 1678, 1631, 1528 cm^{-1} ; $^1\text{H NMR}$ (CDCl_3): δ 1.25-1.50 (s, 18H, Me and m, 2H, CH_2 -3); 1.66 (m, 4H, CH_2 -7 and 8); 2.25 (t, 2H, CH_2CONH); 2.36 (t, 2H, $\text{CH}_2\text{CO}_2\text{H}$); 2.88 (br, 1H, part of AB, CH_2 -4); 3.1 (br, 1H, part of AB, CH_2 -1); 3.24 (br, 1H, part of AB, CH_2 -1); 3.33 (m, 5H, CH-2, part of AB CH_2 -4 and OMe); 5.05 (br, 1H, NH); 5.19 (1H, NH); 7.01 (br, 1H, NH); $^{13}\text{C NMR}$ (CDCl_3): δ 24.4 (C-7); 25.1 (C-8); 28.3 (Me); 32.9 (C-3); 33.7 (C-9); 35.8 (C-4); 36.2 (C-6); 44.4 (C-1); 49.9 (C-2); 51.5 (OMe); 79.6 ($\underline{\text{C}}(\text{Me})_3$); 157.1 (CO_2); 173.0 (CO); 174.0 (CO); Anal. Found: C, 56.74; H, 8.96; N, 9.31. $\text{C}_{21}\text{H}_{39}\text{N}_3\text{O}_7$ requires C, 56.61; H, 8.82; N, 9.43%.

(R,R)-N,N'-Bis[3,4-bis(*t*-butoxycarbonylamino)butyl]urea (14a):

Isocyanate **8a** (595 mg, 1.8 mmol), DMAP (75 mg, 0.62 mmol, and adipic acid (123 mg, 0.85 mmol) were stirred in CHCl_3 (50 mL) for 12 h. The solution was washed with water, citric acid, water, dried (Na_2SO_4) and concentrated, the residue was chromatographed on silica gel column (20 g). Elution with 2.5% MeOH/ CHCl_3 afforded **14a**, 408 mg (71%), mp 190-192°C; $[\alpha]_D^{24} +44.1$ (c 1, EtOH); IR (nujol): 3349, 3367, 1682, 1648, 1640, 1565, 1532 cm^{-1} ; $^1\text{H NMR}$ ($\text{DMSO}-d_6$): δ 1.28-1.49 (m, 4H, CH_2 -3, and s, 36H, Me); 2.80 (m, 2H, part of B, CH_2 -4); 2.91 (m, 4H, CH_2 -1); 3.05 (m, 2H, part of AB CH_2 -4); 3.44 (br, 2H, CH-2); 5.79 (t, 2H, NH-4); 6.56 (d, 2H, NH-2); 6.72 (t, 2H, NH-1); $^{13}\text{C NMR}$ ($\text{DMSO}-d_6$): δ 28.1 (Me); 32.8 (C-3); 36.3 (C-4); 43.8 (C-1); 48.2 (C-2); 77.4 ($\underline{\text{C}}(\text{Me})_3$); 155.4, 155.7 (CO_2); 157.8 (CO); Anal. Found: C, 54.27; H, 8.92; N, 12.86. $\text{C}_{29}\text{H}_{56}\text{N}_6\text{O}_9$ requires C, 55.05; H, 8.92; N, 13.28%.

14a was also isolated in 40% yield as a by-product of **15a** by trituration with EtOAc in which **15a** is soluble.

(S,S)-N,N'-Bis[3,4-bis(*t*-butoxycarbonylamino)butyl]urea (14b):

14b was prepared as described for **14a** and also was isolated as the by-product of **15b**, mp 190-192°C; $[\alpha]_D^{24} -44.7$ (c 1, EtOH); IR (nujol): 3370, 3340, 1680, 1648, 1637, 1552, 1531 cm^{-1} ; $^1\text{H NMR}$ ($\text{DMSO}-d_6$): δ 1.2-1.6 (m, 4H, CH_2 -3, and s, 36H, Me); 2.8 (m, 2H, part of AB, CH_2 -4); 2.96 (m, 4H, CH_2 -1); 3.06 (m, 2H, part of AB CH_2 -4); 3.45 (br, 2H, CH-2); 5.79 (t, 2H, NH-4); 6.53 (d, 2H, NH-2); 6.73 (t, 2H, NH-1); $^{13}\text{C NMR}$ ($\text{DMSO}-d_6$): δ 28.1 (Me); 32.7 (C-3); 36.3 (C-4); 43.8 (C-1); 48.1 (C-2); 77.4 ($\underline{\text{C}}(\text{Me})_3$); 155.3, 155.6 (CO_2); 157.8 (CO); Anal. Found: C, 54.67; H, 9.13; N, 12.96. $\text{C}_{29}\text{H}_{56}\text{N}_6\text{O}_9$ requires C, 55.05; H, 8.92; N, 13.28% NMR

(R)-5-[3,4-Bis(*t*-butoxycarbonylamino)butylaminocarbonyl]pentanoic acid (16a):

Ester **15** (445 mg, 1 mmol) was dissolved in a solution of NaOH in 30 mL MeOH (prepared from 150 mg Na and 0.3 mL water) and left for 12 h at ambient temperature. MeOH was evaporated and water (30 mL) was added. The aqueous layer was acidified upon cooling in ice bath with 5% citric acid, then extracted with ethyl acetate. The organic layer was dried (Na_2SO_4) and

concentrated yielding quantitatively the acid **16a**, mp 43-45°C; $[\alpha]_D^{24} +28.9$ (c 2, EtOH); IR (nujol): 3350, 1741, 1711, 1695, 1648, 1527 cm^{-1} ; ^1H NMR (CD_2Cl_2): δ 1.2-1.5 (m, 2H, CH_2 -3, and s, 18H, Me); 1.65 (t, 4H, CH_2 -7 and 8); 2.22 (t, 2H, CH_2CONH); 2.34 (t, 2H, $\text{CH}_2\text{CO}_2\text{H}$); 2.91 (br, 1H, part of AB, CH_2 -4); 3.14 (br, 2H, CH_2 -1); 3.62 (br, 2H, CH-2 and part of AB, CH_2 -4); 5.11 (br, 1H, NH); 5.21 (1H, NH); 6.77 (br, 1H, NH); ^{13}C NMR (CD_2Cl_2): δ 24.7 (C-7); 25.3 (C-8); 28.5 (Me); 33.1 (C-3); 33.9 (C-9); 36.1 (C-4); 36.5 (C-6); 44.8 (C-1); 50.1 (C-2); 79.9 ($\underline{\text{C}}(\text{Me})_3$); 157.4, 157.5 (NHCO_2); 173.5 (CO); 176.0 (CO); Anal. Found: C, 56.08; H, 8.79; N, 9.30. $\text{C}_{20}\text{H}_{37}\text{N}_3\text{O}_7$ requires C, 55.67; H, 8.64; N, 9.74 %.

(S)-5-[3,4-Bis(*t*-butoxycarbonylamino)butylaminocarbonyl]pentanoic acid (16b):

16b was prepared as described for **16a**, mp 44-46°C; $[\alpha]_D^{24} -29.1$ (c 1.49, EtOH); IR (nujol): 3350, 1741, 1711, 1695, 1648, 1527 cm^{-1} ; ^1H NMR (CD_2Cl_2): δ 1.2-1.5 (m, 2H, CH_2 -3, and s, 18H, Me); 1.65 (t, 4H, CH_2 -7 and 8); 2.22 (t, 2H, CH_2CONH); 2.34 (t, 2H, $\text{CH}_2\text{CO}_2\text{H}$); 2.91 (br, 1H, part of AB, CH_2 -4); 3.14 (br, 2H, CH_2 -1); 3.62 (br, 2H, CH-2 and part of AB, CH_2 -4); 5.11 (br, 1H, NH); 5.21 (1H, NH); 6.77 (br, 1H, NH); ^{13}C NMR (CD_2Cl_2): δ 24.7 (C-7); 25.3 (C-8); 28.5 (Me); 33.1 (C-3); 33.9 (C-9); 36.1 (C-4); 36.5 (C-6); 44.8 (C-1); 50.1 (C-2); 79.9 ($\underline{\text{C}}(\text{Me})_3$); 157.4, 157.5 (NHCO_2); 173.5 (CO); 176.0 (CO); Anal. Found: C, 55.86; H, 9.00; N, 9.21. $\text{C}_{20}\text{H}_{37}\text{N}_3\text{O}_7$ requires C, 55.67; H, 8.64; N, 9.74 %.

***N,N'*-Bis-[3,4-bis(*t*-butoxycarbonylamino)butyl]hexanediamide (17):**

General method: The acid **16** (454 mg, 1 mmol), the isocyanate **8** (289 mg, 0.95 mmol) and DMAP (50 mg) were stirred for 12 h in benzene (70 mL). CHCl_3 (150 mL) was added to dissolve the gelatinous precipitation of the product and of urea. The mixture was washed with 5% citric acid (to remove DMAP), water, 5% aq NaHCO_3 , dried (Na_2SO_4), concentrated and triturated with EtOAc to remove the unreacted acid. The precipitated compounds were filtered, redissolved in 5% MeOH- CHCl_3 to which silica gel (5 g) was added and the solvent was evaporated. The absorbed silica gel was put onto the top of the column prepared from 10 g of silica gel in CHCl_3 . Elution with 1% MeOH/ CHCl_3 removed the urea and the elution with 5% MeOH/ CHCl_3 gave 17.

17a: (from **16a** 348 mg, 0.80 mmol and **8a** 267 mg, 0.81 mmol) 355 mg, 61%; mp 189-190°C; $[\alpha]_D^{24} +36.1$ (c 1.5, EtOH); IR (nujol): 3348, 1681, 1643, 1530 cm^{-1} ; ^1H NMR ($\text{DMSO}-d_6$): δ 1.2-1.50 (m, 44H, $\text{C}(\text{Me})_3$, CH_2 -3, CH_2 -7); 2.02 (t, 4H, CH_2 -6); 2.8-2.9 (m, 6H, CH_2 -1 part of AB, CH_2 -4); 3.06 (m, 2H, part of AB CH_2 -4); 3.45 (br, 2H, CH-2); 6.53 (d, 2H, NH-2); 6.73 (t, 2H, NH-1); 7.67 (t, 2H, NH-4); ^{13}C NMR ($\text{DMSO}-d_6$): δ 24.9 (C-7); 28.1 (Me); 31.7 (C-3); 35.1 (C-6); 35.7 (C-4); 43.8 (C-1); 48.3 (C-2); 77.4, 77.5 ($\underline{\text{C}}(\text{Me})_3$); 155.3, 155.6 (CO_2); 171.6 (C-5); Anal. Found: C, 56.77; H, 9.05; N, 11.33. $\text{C}_{34}\text{H}_{64}\text{N}_6\text{O}_{10}$ requires C, 56.96; H, 9.00; N, 11.72 %.

17b: (from **16b** and **8b**) 429 mg, 68%; mp 189-190°C; $[\alpha]_D^{24} -35.9$ (c 1.5, EtOH); IR (nujol): 3355, 1680, 1645, 1529 cm^{-1} ; ^1H NMR ($\text{DMSO}-d_6$): δ 1.2-1.50 (m, 44H, $\text{C}(\text{Me})_3$, CH_2 -3, CH_2 -7); 2.04 (t, 4H, CH_2 -6); 2.8-2.9 (m, 6H, CH_2 -1 part of AB, CH_2 -4); 3.06 (m, 2H, part of AB CH_2 -4); 3.45 (br, 2H, CH-2); 6.55 (d, 2H, NH-2); 6.70 (t, 2H, NH-1); 7.67 (t, 2H, NH-4); ^{13}C NMR ($\text{DMSO}-d_6$): δ 24.9 (C-7); 28.1 (Me); 31.8 (C-3); 35.2 (C-6); 35.8 (C-4); 43.7 (C-1); 48.3 (C-2); 77.4, 77.5 ($\underline{\text{C}}(\text{Me})_3$); 155.3, 155.7 (CO_2); 171.6 (C-5); Anal. Found: C, 56.92; H, 9.21; N, 11.51. $\text{C}_{34}\text{H}_{64}\text{N}_6\text{O}_{10}$ requires C, 56.96; H, 9.00; N, 11.72 %.

17c: (from **16b** 511 mg, 1.18 mmol and **8a** 397 mg, 1.3 mmol) 585 mg, 69%; mp 200-202°C; $[\alpha]_D^{24} 0.0$ (c 1.5, EtOH); IR (nujol): 3355, 3334, 1681, 1646, 1530 cm^{-1} ; ^1H NMR ($\text{DMSO}-d_6$): δ 1.2-1.50 (m, 44H, $\text{C}(\text{Me})_3$, CH_2 -3, CH_2 -7); 2.8-2.9 (m, 6H, CH_2 -1 part of AB, CH_2 -4); 3.06 (m, 2H, part of AB CH_2 -4); 3.45 (br, 2H, CH-2); 6.53 (d, 2H, NH-2); 6.73 (t, 2H, NH-1); ^{13}C NMR ($\text{DMSO}-d_6$): δ 25.0 (C-7); 28.3 (Me); 31.8 (C-3); 35.3 (C-6); 35.9 (C-4); 43.9 (C-1); 48.4 (C-2); 77.4, 77.5 ($\underline{\text{C}}(\text{Me})_3$); 155.4, 155.8 (CO_2); 171.6 (C-5); Anal. Found: C, 56.77; H, 8.84; N, 11.66. $\text{C}_{34}\text{H}_{64}\text{N}_6\text{O}_{10}$ requires C, 56.96; H, 9.00; N, 11.72 %.

ACKNOWLEDGEMENT

We are indebted to Professor Klaus Wanner of the Institute of Pharmacy, University of München for fruitful discussions. Thanks are due to Mrs. Aniane Huber-Loth and Mr. Ulrich Weber for their help in HPLC experiments and to Mr. Peter Mayer for performing NMR spectra. Support by the Deutsche Forschungsgemeinschaft is gratefully acknowledged.

REFERENCES AND NOTES

[†] Dedicated to the memory of Professor Dov Ben-Ishai.

1. a) Lippard, S. J. *Pure Appl. Chem* **1987**, *59*, 731-742. b) Reedijk, J. *Pure Appl. Chem* **1987**, *59*, 181-192. c) Brunner, H., Hankofer, P., Treitinger, B. *Chem. Ber.* **1990**, *123*, 1029-1038. d) Gust, R., Burgemeister, T., Mannschreck, A., Schoenberger, H. *J. Med. Chem.* **1990**, *33*, 2535-2544.
2. a) Vlassov, V. V., Gorn, V. V., Ivanova, I. M., Kazakov, S. A., Mamaev, S. V. *FEBS Lett.* **1983**, *162*, 286-289. b) Farrell, N., Qu, Y., Feng, L., van Houten, B. *Biochemistry* **1990**, *29*, 9522-9531. c) Alul, R., Cleaver, M. B., Taylor, J.-S. *Inorg. Chem.* **1992**, *31*, 3636-3646. d) Van Houten, B., Illenye, S., Qu, Y., Farrell, N. *Biochemistry*, **1993**, *32*, 11794-11801. e) Ling, E. C. H., Allen, G. W., Hambley, T. W. *J. Am. Chem. Soc.* **1994**, *116*, 2673-2674. f) Zou, Y., Van Houten, B., Farrell, N. *Biochemistry*, **1994**, *33*, 5404-5410. g) Qu, Y., Farrell, N. *Inorg. Chem.* **1995**, *34*, 3573-3576.
3. Schuhmann, E., Altman, J., Karaghiosoff, K., Beck, W. *Inorg. Chem.* **1995**, *34*, 2316-2322.
4. Büning, H., Zorbas, H. Seventh International Conference on Bioinorganic Chemistry, Luebeck, September 3-8, 1995.
5. Altman, J., Ben-Ishai, D., Beck, W. *Tetrahedron Asymmetry*, **1994**, *5*, 887-894.
6. a) Altman, J., Ben-Ishai, D. *Tetrahedron Asymmetry*, **1993**, *4*, 91-101. b) Altman, J., Ben-Ishai, D., Berkovich, E. *Tetrahedron*, **1993**, *49*, 2515-2520.
7. a) Silverman, R. B., Levy, M. A. *J. Org. Chem.* **1980**, *45*, 815-818. b) Saijo, S., Wada, M., Himizu, J.-I., Ishida, A. *Chem. Pharm. Bull.* **1980**, *28*, 1449-1458.
8. Mitsunobu, O. *Synthesis*, **1981**, 1-28.
9. Hoefle, G., Steglich, W., Vorbrüggen, H. *Angew. Chem.* **1978**, *90*, 602-615. *Angew. Chem. Int. Ed. Engl.* **1978**, *17*, 569-582.
10. Altman, J., Schuhmann, E., Karaghiosoff, K., Eichen-Karaghiosoff, E., Beck, W. *Z. Naturforsch.* **1991**, *46b*, 1473-1488.
11. a) Hutchins, S. M., Chapman, K. T. *Tetrahedron Lett.* **1994**, *35*, 4055-4058. b) Hutchins, S. M., Chapman, K. T. *Tetrahedron Lett.* **1995**, *36*, 2583-2586.
12. Koninklijke Nederlandsche Gist-en Spiritusfabriek N. V. *Ger. Offen.* 2. 155, 152; *Chem. Abstr.* **1972**, *77*, 88491j.

(Received in Germany 25 August 1995; accepted 30 September 1995)